

Strategies to avoid lack of response of Immunobiological drugs delivered subcutaneously

Patricia Fabrini, Marco Araujo, Luísa Coutinho Teixeira and Marina Rodrigues Costa Lages

Santhè Clinic, Brazil


The present work aims to highlight different ways to prevent diminished or lack of response of immunobiological drugs delivered subcutaneously, therefore reducing the burden of treatment with immunobiological drugs for both patients and healthcare system. Etanercept is an immunobiological drug with anti-TNF action, applied subcutaneously, which is indicated in cases of psoriasis refractory to other treatments. The present study shows a possible lack of response to the treatment

after consecutive applications in the same anatomical site.

Speaker Biography

Patricia Fabrini holds an infusional center in Belo Horizonte, Minas Gerais, Brazil. She also works as a dermatologist in Santa Casa, a great hospital in the city. She is nowadays responsible for the infusion of many of the patients diagnosed with immunomediated diseases, like Psoriasis, Arthritis, Crohn's disease and Ankylosing Spondylitis where patients with psoriasis and arthritis receive immunobiological treatment.

e: saudesanthe@hotmail.com

 *Notes:*